WO2003049775A2 - Copolymer coating for a hydrophobic membrane - Google Patents
Copolymer coating for a hydrophobic membrane Download PDFInfo
- Publication number
- WO2003049775A2 WO2003049775A2 PCT/US2002/039171 US0239171W WO03049775A2 WO 2003049775 A2 WO2003049775 A2 WO 2003049775A2 US 0239171 W US0239171 W US 0239171W WO 03049775 A2 WO03049775 A2 WO 03049775A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- hydrophobic
- solution
- copolymer
- dialyzer
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 292
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 80
- 229920001577 copolymer Polymers 0.000 title claims abstract description 67
- 238000000576 coating method Methods 0.000 title claims abstract description 63
- 239000011248 coating agent Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000008280 blood Substances 0.000 claims description 87
- 210000004369 blood Anatomy 0.000 claims description 86
- 229920002492 poly(sulfone) Polymers 0.000 claims description 80
- 239000000126 substance Substances 0.000 claims description 76
- 238000000502 dialysis Methods 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 30
- 238000001631 haemodialysis Methods 0.000 claims description 18
- 230000000322 hemodialysis Effects 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001179 sorption measurement Methods 0.000 claims description 13
- 230000008021 deposition Effects 0.000 claims description 12
- 239000004695 Polyether sulfone Substances 0.000 claims description 10
- 229920006393 polyether sulfone Polymers 0.000 claims description 10
- 208000020832 chronic kidney disease Diseases 0.000 claims description 9
- 208000028208 end stage renal disease Diseases 0.000 claims description 9
- 201000000523 end stage renal failure Diseases 0.000 claims description 9
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical group C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 5
- 230000001951 hemoperfusion Effects 0.000 claims description 4
- 238000005086 pumping Methods 0.000 claims description 4
- 238000001223 reverse osmosis Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 239000008367 deionised water Substances 0.000 claims 2
- 229910021641 deionized water Inorganic materials 0.000 claims 2
- 238000002615 hemofiltration Methods 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 1
- 229920000428 triblock copolymer Polymers 0.000 abstract description 25
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 abstract description 20
- 239000003446 ligand Substances 0.000 abstract description 15
- 239000000463 material Substances 0.000 abstract description 15
- 239000000243 solution Substances 0.000 description 105
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 26
- 239000011148 porous material Substances 0.000 description 26
- 239000000835 fiber Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 229920001451 polypropylene glycol Polymers 0.000 description 20
- 239000012510 hollow fiber Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 230000035602 clotting Effects 0.000 description 13
- 238000000151 deposition Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 206010053567 Coagulopathies Diseases 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 108010017384 Blood Proteins Proteins 0.000 description 8
- 102000004506 Blood Proteins Human genes 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 238000004626 scanning electron microscopy Methods 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102220499613 Dysferlin_F80A_mutation Human genes 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000001878 scanning electron micrograph Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- WGGFHAVVTPGHRD-UHFFFAOYSA-N 2-(pyridin-2-yldisulfanyl)ethanamine Chemical compound NCCSSC1=CC=CC=N1 WGGFHAVVTPGHRD-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical group [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000004375 Angiodysplasia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 1
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 1
- JYAXYNMOHKXUNL-UHFFFAOYSA-N [Na].C=CC#N Chemical compound [Na].C=CC#N JYAXYNMOHKXUNL-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0088—Physical treatment with compounds, e.g. swelling, coating or impregnation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3673—Anticoagulant coating, e.g. Heparin coating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/021—Manufacturing thereof
- B01D63/0231—Manufacturing thereof using supporting structures, e.g. filaments for weaving mats
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0093—Chemical modification
- B01D67/00933—Chemical modification by addition of a layer chemically bonded to the membrane
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/0427—Coating with only one layer of a composition containing a polymer binder
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/056—Forming hydrophilic coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L81/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing sulfur with or without nitrogen, oxygen or carbon only; Compositions of polysulfones; Compositions of derivatives of such polymers
- C08L81/06—Polysulfones; Polyethersulfones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D171/00—Coating compositions based on polyethers obtained by reactions forming an ether link in the main chain; Coating compositions based on derivatives of such polymers
- C09D171/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
- C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2471/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
Definitions
- Hydrophobic membranes have many practical uses in a variety of areas, including the medical field. For example, hydrophobic membranes can be used in medical procedures to extract or remove wastes from a patient's body fluids.
- a patient's blood comes in contact with many parts of the dialysis system, including the semipermeable membrane inside the dialyzer, and these parts of the system need to be biocompatible. As the blood contacts the membrane, problems can occur if the membrane surfaces are not biocompatible.
- membrane surfaces have a propensity to adsorb substances or molecules, such as proteins, which can create problems for the patient during dialysis treatment.
- proteins can be adsorbed or deposited on the surface of the membrane, initiating the coagulation of blood along the membrane surface. This is dangerous for the patient because if coagulated blood is returned to the patient, it can block an artery or vein in the patient and prevent blood from flowing throughout the patient's body.
- the deposition of substances or molecules, such as proteins, in the blood along the surface of the membrane varies depending upon the surface properties of the membrane and the composition of the blood.
- polysulfone or polyethersulfone membranes are often used in dialyzers because these materials are fairly biocompatible as they respond better than other types of membrane materials to the patient's blood during dialysis.
- the membrane When blood comes in contact with the membrane, it can activate several enzymatic pathways, such as the complement system and the coagulation cascade.
- leukocytes and platelets can be activated as well.
- the polysulfone membrane was developed to help minimize the activation of the complement system.
- composition of the patient's blood is usually altered and monitored to reduce the chance of blood clotting during treatment.
- a patient's fluid and electrolyte inlet maybe regulated to help reduce the risk of blood coagulation during treatment.
- medication such as the sulfated polysulfone anticoagulant heparin, can be administered to dialysis patients to thin the blood and reduce the chance that blood coagulation will occur during treatment.
- the inhibitory effect of heparin on blood coagulation is due to the chains of heparin being able to bind with the plasma protein antithrombin HI and thrombin to form the thrombin-antithrombin HI complex.
- a patient's blood is pumped through a dialyzer wherein substances can be removed from or added to the blood as substances flow to and from the blood across a semipermeable membrane in the dialyzer.
- substances in the patient's blood that are too large to pass through the pores of the membrane, such as plasma proteins, can adsorb or deposit on the surface of the membrane creating a surface-induced thrombosis reaction.
- Membrane materials that help reduce and minimize the adsorption or deposition of substances, such as plasma protein, on the surface of the membrane during dialysis treatment are beneficial to patients because they help reduce the risk of problems occurring to the patient.
- the properties of the membrane surface can be altered with surface modification techniques to help reduce the chance of adsorption on the membrane surface, thereby reducing the risk of a dangerous reaction.
- a coating on the membrane surface can be used to help reduce the adsorption or deposition of substances on the membrane surface during dialysis treatment.
- Copolymers with at least one hydrophobic segment and at least one hydrophilic segment have been found to attach to the surface of hydrophobic membranes, coating the membrane surface and reducing the adsorption or deposition of substances on the membrane surface.
- polyethylene oxide (PEO) and polypropylene oxide (PPO) copolymers can be immobilized on the surface of a polysulfone membrane, coating the membrane surface.
- the PPO segments are hydrophobic and will attach to the surface of a hydrophobic membrane.
- the PEO segments are hydrophilic and will not attach to the membrane surface, but will extend into a hydrophilic enviromnent.
- the resulting copolymer can be used to coat a polysulfone membrane surface and help repel or prevent molecules from contacting the surface of the membrane, thereby reducing the chance that those molecules will adsorb or deposit on the membrane surface. This helps to minimize the surface-induced thrombosis reaction that can occur on the surface of the polysulfone membrane during dialysis treatment.
- the copolymer coating can be applied to the membrane by exposing the membrane surface to a solution of the copolymers dissolved in water.
- a PEO-PPO-PEO copolymer can be dissolved in water to form the copolymer solution.
- the copolymer solution can be pumped through the dialyzer and the PEO-PPO-PEO triblock copolymers will attach to and coat the surface of the hydrophobic membrane.
- the copolymer solution can be pumped through only the blood compartment of a dialyzer so that the surface of the membrane facing the blood compartment is coated with the copolymers.
- the solution can also be pumped through both the blood compartment and the dialysate compartment of a dialyzer so that both sides of the membrane are coated with the copolymers.
- FIG. 1 is a diagram of a patient undergoing dialysis treatment.
- FIG. 2 is a diagram of a dialyzer and the inlet and outlet tubes connected to the dialyzer.
- FIG. 2A is an enlarged cross-section diagram showing individual fibers in the dialyzer during treatment.
- FIG. 3 is an enlarged diagram showing the diffusion of smaller molecules across a semipermeable membrane.
- FIG. 4 is an enlarged cross-section diagram of the semipermeable membrane surface that has been coated on one side with a PEO-PPO-PEO triblock copolymer coating.
- FIG. 5 shows a system used to single coat the semipermeable membrane in a dialyzer.
- FIG. 6 shows a system used to double coat the semipermeable membrane in a dialyzer.
- FIG. 7 is a graph showing the binding energy spectrum from the x-ray photoelectron spectroscopy of the surface of a coated polysulfone membrane.
- FIG. 8 is a graph showing the summarized CI peaks for an uncoated and coated polysulfone membrane.
- FIG. 9 is a graph showing the summarized 01 peaks for an uncoated and coated polysulfone membrane.
- FIG. 10 (A) and (B) are photographs from a scanning electron microscopy of a double coated and an uncoated polysulfone membrane at 5 kb'X 30 k.
- FIG. 11 (A) and (B) are photographs from a scanning electron microscopy of a double coated and an uncoated polysulfone membrane at 5 kb X 10 k.
- FIG. 12 (A) and (B) are photographs from a scanning electron microscopy of a double coated and an uncoated polysulfone membrane at 5 kb X 30 k.
- FIG. 13 shows the chemistry of the synthesis of the PluronicTM F108 coating used in the labeled PluronicTM F 108 test.
- FIG. 14 is a bar graph showing the average clotting time for samples of various membranes as compared to the negative control sample.
- Hemodialysis also called dialysis
- dialysis is a medical procedure for patients with conditions such as renal failure where the patient's kidneys are no longer removing unwanted substances from the patient's blood.
- the patient's blood is cycled through a hemodialysis system so that unwanted substances are filtered from and/or wanted substances are added to the blood in a dialyzer.
- Patients who need this treatment may undergo the dialysis process several times each week so that these unwanted substances are regularly filtered from and/or wanted substances are regularly added to their blood.
- FIG. 1 shows a patient 101 undergoing dialysis treatment with a hemodialysis system 102.
- the hemodialysis system 102 can be comprised of many different components and configured in a variety of ways.
- a patient is generally connected to the hemodialysis system 102 by an arterial line 103 and a venous line 104 during the treatment.
- the patient's blood is drawn from the patient 101 through the arterial line 103 by a pump 105 that is part of the hemodialysis system 102.
- the blood is pumped from the arterial line 103 into the dialyzer 106.
- the patient's blood flows through the dialyzer 106 where unwanted substances are filtered from or wanted substances are added to the blood..
- the patient's blood is returned to the patient 101 through the venous line 104 of the hemodialysis system 102.
- the dialyzer acts as an "artificial kidney” and is used to filter unwanted substances from or add wanted substances to the patient's blood.
- the dialyzer is generally comprised of four basic parts: a casing, usually made of plastic; a blood compartment; a dialysate compartment; and one or more semipermeable membranes separating the blood compartment from the dialysate compartment.
- dialyzers can be designed in many ways, the three most common designs for dialyzers have traditionally been the coil dialyzer, the parallel plate dialyzer and the hollow fiber dialyzer. Each of these designs work on the same principles, but the shape of the area or compartment for the patient's blood and the area or compartment for dialysate solution as well as the configuration of the semipermeable membrane are different. While this specification uses the hollow fiber dialyzer design to explain the invention disclosed herein, it can be appreciated by one skilled in the art that the invention could be used with any type of hydrophobic membrane, including membranes used in other types of dialyzers and other pieces of medical equipment.
- the hollow fiber dialyzer 201 contains thousands of capillary-sized hollow fibers 202 made of a semipermeable membrane material that reach from one end of the dialyzer to the other end of the dialyzer. Each fiber may be as thin as a human hair with an internal diameter of approximately 150-300 microns. Fluid, such as the patient's blood, can flow through the hollow fibers 202.
- the fibers are usually held in place at each end of the dialyzer by a clay-like polyurethane "potting" material 203, which serves as the support structure for the hollow fibers 202.
- the hollow fibers 202 and structural support material 203 are enclosed in the plastic casing 204.
- the patient's blood is pumped through the arterial line 210 and into an inlet chamber 211 at one end of the dialyzer 201.
- the blood then flows from the inlet chamber 211 through the hollow fibers 202, where it is filtered, and into an outlet chamber 213 at the other end of the dialyzer 201.
- the filtered blood is returned to the patient through the venous line 214.
- the dialysate solution is pumped into the end of the dialyzer that contains the outlet chamber 213 through a dialysate inlet tube 216.
- the dialysate solution then flows in between the hollow fibers 202 to the end of the dialyzer that contains the inlet chamber 211 for the patient's blood. As shown in FIG.
- the dialysate solution 219 can be flowing in between the hollow fibers in the direction shown by arrow 221. This creates a countercurrent flow as " blood flows inside the hollow fibers in one direction (e.g., top to bottom in the diagram) and the dialysate flows around the hollow fibers in the opposite direction (e.g., bottom to top in the diagram).
- the dialysate solution then flows out of the dialyzer 201 through the dialysate outlet tube 217.
- the semipermeable membrane has microscopic pores and generally divides the dialyzer into two separate areas or compartments: one area for the patient's blood and one area for the dialysate solution.
- the patient's blood is on one side of the semipermeable membrane and the dialysate solution is on the other side of the membrane.
- the semipermeable membrane is not necessarily one contiguous membrane, but may be comprised of several separate membranes that generally divide the dialyzer into two distinct areas. For example, in the hollow fiber dialyzer, each hollow fiber is made of the semipermeable membrane material.
- Unwanted substances are removed from and/or wanted substances are added to the patient's blood by flowing through the pores in the semipermeable membrane between the blood and dialysate solution.
- the substances flow through the pores in the membrane as a result of diffusion and/or pressure differentials between the blood 218 and dialysate solution 219 on either side of the membrane. Under the principle of diffusion, substances will move, where possible, from an area of greater concentration to an area of lesser concentration.
- the dialysate solution acts as a buffer solution and is typically an electrolyte solution that contains substances such as purified water, sodium, potassium, calcium, magnesium, chloride and dextrose.
- the dialysate solution helps to regulate the flow of substances and molecules through the membrane by creating the concentration gradient.
- the concentration of the substances or molecules in the dialysate solution can be adjusted to increase or decrease the gradient for those substances that need to be filtered from or added to the patient's blood. If a substance has molecules small enough to pass through the pores of the semipermeable membrane, the concentration gradient between the blood and the dialysate solution can- cause that substance to move from the patient's blood to the dialysate solution if the concentration of that substance is greater in the patient's blood. Conversely, the concentration gradient can cause a substance to move from the dialysate solution to the blood if the concentration of that substance is greater in the dialysate solution. Therefore, the concentration of substances in the dialysate solution can be adjusted to target the removal or addition of certain substances from the patient's blood.
- the semipermeable membrane has microscopic pores that allow only certain sized molecules, such as specific solutes, electrolytes and water, to pass through the membrane.
- the - size of these pores prevents larger molecules in the blood, such as medium sized proteins or red blood cells, from diffusing across the membrane into the dialysate solution.
- the patient's blood 301 is separated from the dialysate solution 302 by the semipermeable membrane 303.
- Substances or molecules that are too large to pass through the pores of tire semipermeable membrane are unable to diffuse across the membrane 303 and remain in the patient's blood or dialysate solution.
- Substances and molecules that are small enough to pass through the pores in the semipermeable membrane 303 can diffuse between the patient's blood 301 and the dialysate solution 302 depending upon the relative concentration of those substances in the blood 301 and the dialysate solution 302.
- Plasma proteins in the blood can adsorb or deposit on the surface of the polysulfone membrane which can result in a membrane surface-induced thrombosis reaction.
- the plasma proteins are larger molecules that cannot pass through the microscopic pores of the semipermeable membrane, but can adsorb or deposit on the surface of the membrane.
- the total amount of plasma protein found on the membrane surface after filtration has been as low as 400 mg/m 2 or as high as 2,600 mg/m 2 .
- the range of total plasma protein found on the membrane surface depends, at least in part, on the membrane material used in the dialyzer. Therefore, it is important to use membrane materials that will help reduce and minimize protein adsorption and deposition on the surface of the membrane during the dialysis treatment.
- PEO and PEG are biocompatible materials that can be used to modify the surface of hydrophobic membranes.
- PEO and PEG can be attached to other substances that can be knmobilized onto the surface of a polysulfone membrane by processes such as wet chemical reaction, plasma grafting, electron beam irradiation or physical adsorption methods.
- PEO chains are hydrophilic so that they will not attach to a hydrophobic membrane surface, but they will extend into a hydrophilic environment such as the patient's blood.
- the resulting copolymer can be used to coat a hydrophobic membrane surface.
- These copolymers can be used to minimize the surface-induced thrombosis reaction that can occur on the surface of a polysulfone membrane during dialysis treatment. While these copolymers have been found to work particularly well for coating the surfaces of membranes used in dialysis treatment, it will be appreciated by one skilled in the art that these copolymers can be used to coat the surfaces of membranes for other purposes as well.
- copolymers that have a hydrophobic segment and hydrophilic segment and can be used to coat hydrophobic membrane surfaces.
- One group of copolymers that has been found to work particularly well for coating membrane surfaces are PEO-PPO-PEO triblock copolymers. These copolymers are commercially available from BASF and sold under the trademark name of PluronicsTM. These copolymers have been used to modify the surface of hydrophobic polystyrene.
- the PEO-PPO-PEO triblock copolymers work well because the hydrophobic PPO segment attaches to the surface of the hydrophobic membrane and the hydrophilic PEO segments on either side of the PPO segment extend from the membrane surface into the patient's blood, helping to repel larger molecules in the patient's blood and prevent them from adsorbing or depositing on the surface of the membrane.
- the PEO segments can be attached to both ends of a PPO segment.
- the PPO segment will adsorb on hydrophobic substrates, such as polystyrene or polysulfone, by hydrophobic interactions.
- hydrophobic PPO segment When the hydrophobic PPO segment has adsorbed onto the polysulfone membrane surface, the hydrophilic PEO segments extend from the PPO segment into the hydrophilic environment and help repel substances and molecules from the surface of the membrane, preventing the substances and molecules from contacting the' surface of the polysulfone membrane.
- the hydrophobic surface of the polysulfone membrane is essentially turned into a hydrophilic surface.
- the membrane 401 can be coated with PEO-PPO-PEO triblock copolymers 402.
- the membrane 401 is porous so that certain sized molecules and substances can pass through the pores in the membrane 401. Only the top side of the membrane, which faces the blood compartment in the dialyzer, has been coated in this FIG..
- the PEO-PPO-PEO triblock copolymers coat the membrane, the PPO segment 411 of the PEO-PPO-PEO triblock copolymer 402 adsorbs on the membrane surface.
- the PEO segments 411 which are attached on either end of the PPO segment 410 do not adsorb to the membrane surface 401, but extend into the hydrophilic environment.
- the copolymers will help prevent larger molecules in the blood from contacting the membrane surface.
- Larger molecules such as albumin 403 are unable to pass through the microscopic pores in the semipermeable membrane 401. Therefore, they cannot pass through the membrane from the blood into the dialysate.
- medium sized molecules such as ⁇ 2 -microglobulin 404 and smaller molecules such as urea 405 can pass through the microscopic pores in the semipermeable membrane 401 and pass from one side of the membrane to the other.
- the copolymer coating helps prevent larger molecules from contacting the membrane surface and increasing the risk of blood coagulation or other dangers to the patient undergoing dialysis treatment, but does not prevent smaller molecules from passing through the pores in the membrane.
- Other substances or molecules can be targeted for removal from a patient's blood by immobilizing ligands on the copolymers used to coat the membrane.
- the immobilized ligands will extract specific targets, such as protein, from the patient's blood because the targets will bind to the immobilized ligands.
- an active group can be added to the copolymer used for coating the membrane surface.
- the active group can be attached to the end of the PEO segment that is not attached to the PPO segment.
- the active group will bind to certain ligands, thereby immobiUzing the ligands on the copolymer.
- a modified PEO-PPO-PEO triblock copolymer where at least one of the PEO segments has an organic metal-chelating end group (R) attached to its end is disclosed in U.S. Patent No. 6,087,452.
- This type of modified surfactant can also be used to coat the surface of a hydrophobic membrane.
- the ligands are immobilized on the surfactant through the metal-chelating end group.
- active groups can also be used to immobilize ligands on the copolymers so that the ligands can bind with targets.
- U.S. Patent No. 5,516,703 discloses other examples of active groups, such as the primary amine NH 2 group orpyridyl disulfide group. When used to coat the surface of dialyzer membranes, these other active groups and ligands can also be used to remove specific targets from the patient's blood.
- the modified copolymer with the ligands immobilized by an active group serves the dual purpose of repelling biological molecules, such as protem, from adsorbing or depositing on the membrane surface and extracting from the patient's blood specific targets, such as protein, as they bind to the immobilized ligands.
- biological molecules such as protem
- the copolymer coating with an active group can immobilize ligands, such as antibodies, that will bind with targets, such as protein, thereby extracting that specific target from the patient's blood.
- the membrane surface can be coated with copolymers in many different ways.
- a hydrophobic segment such as PPO
- PEO polysulfone
- a copolymer with a hydrophobic segment will adsorb to the polysulfone membrane surface when a solution containing the copolymer is exposed to the surface of the polysulfone membrane for a period of time. This has been found to work particularly well with the PEO-PPO-PEO triblock copolymer.
- This method can be used to coat a hydrophobic membrane in a dialyzer.
- a solution containing the triblock copolymer can be pumped througli the dialyzer after the dialyzer has been assembled.
- the membrane in the dialyzer will be exposed to the solution as the solution is pumped througli the dialyzer and the triblock copolymer will adhere to and coat the hydrophobic membrane surface.
- PEO-PPO-PEO triblock copolymers are a powdered substance that can be ' dissolved in water to create a solution that can be used to coat a membrane.
- PluronicTM F68 [(PEO) 76 -(PPO) 3 o-(PEO) 7 ⁇ ]
- PluronicTM F88 ' [(PEO) 104 -(PPO) 39 -(PEO) 10 ]
- PluronicTM F108 [(PEO) ⁇ 29 -(PPO) 56 - (PEO) ⁇ 29 ].
- the chemical structure formula for these three Pluronic surfactants is:
- copolymers with at least one hydrophobic segment and at least one hydrophilic segment can be used as well.
- the PEO-PPO-PEO triblock copolymer solution can be pumped through the dialyzer!
- the hydrophobic segment of the triblock copolymer will adhere to the surface of the hydrophobic membrane, thereby coating it as the solution contacts the membrane surface.
- This coating process has been found to work particularly well when the PEO-PPO-PEO triblock copolymers are dissolved in reverse osmosis deionized (RO DI) water to form an approximately 0.2% (weight/volume) solution. While the coating process will work when the weight/volume of the solution is greater or less than 0.2%, the weight/volume of the solution should be less than the critical gel point for the solution so that the solution can easily flow through a dialyzer.
- the critical gel point for a solution of PluronicTM F108. is approximately 3% (weight/volume) .
- the solution must be maintained at a temperature above freezing, and it is believed that the coating process will work well when the solution has a temperature greater than 20°C.
- This coating process for a dialyzer membrane has been found to work particularly well when the solution is maintained at a temperature of about 37°C, which is the normal temperature for human blood.
- the coating process has been found to work particularly well when the solution is pumped through the dialyzer at a flow rate of approximately 300 ml/minute. While the solution can be pumped through the dialyzer for more or less time, it has been found that pumping the approximately 0.2% (weight/volume) solution through the dialyzer at a flow rate of approximately 300 ml/minute for approximately 30 minutes is a sufficient amount of time for the PEO-PPO-PEO triblock copolymers in the solution to coat the surface of the polysulfone membrane.- It will be appreciated by one skilled in the art that the coating process does not have to take place after a membrane has been assembled in a dialyzer. For example, a hydrophobic membrane could be coated with a copolymer by immersing the membrane in a reservoir of the copolymer solution.
- the membrane can be coated with a single coating process whereby the copolymer solution is pumped through only the blood compartment of the dialyzer.
- one pump 502 is used to pump the solution from a reservoir of solution 501 into the outlet chamber 503 of the dialyzer 507.
- the solution flows up through the hollow fibers in the dialyzer 507 and into the inlet chamber 504 of the dialyzer 507.
- the inlet chamber 504 is filled with the solution, the solution flows out of the inlet chamber 504 and can be returned to the reservoir of solution 501 to be reused in the coating process.
- the dialysate inlet tube 505 is plugged so that any part of the copolymer solution that passes through the membrane cannot leave the dialyzer through the dialysate inlet tube 505. Therefore, the dialysate compartment may also fill up with the solution to the extent the solution passes through the semipermeable membrane during the coating process. If the dialysate compartment fills up with solution during the single coating process, the solution can be returned to the reservoir of solution 501 through the dialysate outlet tube 506. Alternatively, the dialysis outlet tube 506 can be plugged so that the solution can only exit the dialyzer 507 through the inlet chamber 504 of the dialyzer 507.
- the membrane can also be coated with a double-coating process whereby the copolymer solution is pumped through both the blood compartment and the dialysate compartment of the dialyzer.
- two pumps 602 are used to pump the solution from the reservoir of solution 601 through the dialyzer 607.
- the solution is pumped from the reservoir 601 into both the outlet chamber 603 and the dialysate inlet tube 605.
- the outlet chamber 603 fills with the solution
- the solution flows up through the hollow fibers in the dialyzer 607 and into the inlet chamber 604 of the dialyzer 607.
- the inlet chamber 604 is filled with the solution, the solution once again flows out of the inlet chamber 604 and can be returned to the reservoir of solution 601 to be reused in the coating process.
- the dialysate chamber of the dialyzer 607 is being filled with the solution and the solution flows up around the hollow fiber of the dialyzer 607, filling the dialysate chamber of the dialyzer 607:
- the dialysate compartment is filled with the solution
- the solution flows out of the dialysate outlet tube 606 and can be returned to the reservoir of solution 601 to be reused in the coating process.
- both sides of the membrane are directly exposed to the copolymers in the solution and are therefore coated.
- One major advantage to using this process to coat a membrane for a dialyzer over other methods, such as coating the membrane before the dialyzer is assembled is that the membrane coating process can take place after the dialyzer has been assembled. Therefore, additional steps would not have to be added to alter or change the existing dialyzer production process.
- the membrane is coated after it is in place in the dialyzer making it less likely that the coating will be disrupted before the dialyzer is used in treatment.
- the surface of the coated polysulfone membrane was coated with PluronicTM F108 using the double coating process described above.
- a solution with approximately 0.2% (weight/volume) of the F108 was pumped through both the blood compartment and the dialysate compartment at approximately 300 ml/minute for approximately 30 minutes.
- XPS X-ray photoelecfron specfroscopy
- SEM scanning electron microscopy
- PluronicTM surfactant a labeled PluronicTM surfactant
- XPS Electron Specfroscopy for Chemical Analysis
- Electron Specfroscopy is generally used to analyze the surface characterization of biomedical polymers. This analysis provides a total elemental analysis of the top 10 ⁇ 200 A of the membrane surface, thereby revealing what elements comprise the membrane surface.
- FIG. 7 shows that all four major elements, sulfur, carbon, oxygen and nitrogen, were present on the surface of a polysulfone fiber from the coated membrane surface.
- the carbon, oxygen and sulfur were expected because they are part of the chemical structure of the polysulfone.
- the reasons for the presence of nitrogen on the surface of the polysulfone fiber is not readily apparent because there is no nitrogen in the chemical structure of polysulfone or the PEO-PPO-PEO triblock copolymer used to coat the membrane.
- the presence of nitrogen on the polysulfone fiber is probably left from the use of polyvinyl pyrrolidone (PVP) in the process to make the polysulfone fibers. Since the XPS survey scan shows the presence of nitrogen on the membrane surface, this indicates that the PNP was present on the surface of the polysulfone membrane, indicating that the PNP adhered to the membrane surface.
- PVP polyvinyl pyrrolidone
- the C-0 peak for the coated polysulfone fiber was greater than the peak for the uncoated polysulfone fiber (solid line) and shifted to a lower binding energy. This peak indicates that the F108 copolymer adhered and bound to the polysulfone fiber surface.
- the Ols peak for the uncoated polysulfone fiber is also significantly different than the peak for the coated polysulfone fiber.
- the XPS spectrum shows the chemical analysis for the surface of the fibers.
- a summary of the chemical analysis in this study is listed in Table 1.
- the most significant change in atomic percentages between the uncoated and the coated polysulfone fibers was for the oxygen atom.
- the oxygen content of the coated polysulfone fiber increased 3% (form 12.5% to 15.5%).
- Most of this oxygen should have come from the F108 coating.
- the carbon content did not change much due to the large amount of the carbon atom also found in the F108.
- the nitrogen content was decreased 4.4% (from 6.7% to 2.3%) because there was no additional nitrogen on the polysulfone fiber surface after the polysulfone fiber was coated with the F108.
- the SEM microscope produces high resolution images, which allow closely spaced features of an object to be examined at a high magnification.
- the SEM microscope was used to compare the inside and outside surface of the uncoated polysulfone membrane and the coated polysulfone membrane. Both polysulfone fibers were coated with a thin layer of platinum under a vacuum for 90 seconds (approximately 1 nm) to make the fibers conductive so that they could be examined using this process.
- FIGS. 10-12 The SEM images for the uncoated and coated polysulfone fibers are shown in FIGS. 10-12.
- image (a) is the uncoated polysulfone membrane and image (b) is the double coated polysulfone membrane.
- FIG. 10 contains SEM images for the inside surface of the polysulfone membranes at 5 kb X 30 k.
- FIG. 11 contains SEM images for the outside surface of the polysulfone membranes at 5 kb X 10 k.
- FIG. 12 contains SEM images for the outside surface of the polysulfone membranes at 5 kb X 30 k.
- FIGS. 12(a) and (b) are used to determine whether the coating is on the surface of the non-porous regions of the coated membrane. An analysis of FIG. 12(a) and (b) indicate no significant difference. In fact, all the SEM images show no significant difference between the uncoated membrane and the coated membrane. This indicates that the F108 coating did not block the pores of the polysulfone fiber membrane.
- the labeled PluronicTM F108 test quantitatively determines the amount of F108 coating on the dialyzer surface in terms of the surface coverage of the F 108.
- the labeled PluronicTM F108 has probe molecules covalently bound to the F 108. This probe molecule can be a radioisotope, fluorescent or colorimetric molecule.
- the pyridyl disulfide (“PDS”) group covalently bound to the PEO end of the F108 molecule was selected in this study because of its stability in the aqueous solution. The chemistry of the synthesis of F108-PDS is shown in FIG. 13 and the detailed procedure for this portion of the test can be found in the following publication: J-T. Li, J. Carlsson, J-N Lin and K. D.
- the experimental procedure used was as follows: a liter of 0.2% FI 08-PDS solution was prepared for the dialyzer coating process. The single coating process was used and 0.2% F108- PDS solution was pumped through the blood side of a F80A dialyzer at 37°C for 30 minutes. At the end of the single coating process, the F108-PDS solution flowed back to the reservoir. A sample of the FI 08-PDS before and after the coating process was collected from the solution reservoir to determine the amount of F108 that was depleted from the solution during the coating process.
- RO DI water was then pumped through the blood compartment of the dialyzer for another
- F108-PDS Prior to the analysis of F108-PDS, the F108-PDS was characterized for the degree of labeling (i.e., how many PDS molecules covalently bound to each F108 molecule).
- a 2 ml FI 08-PDS solution with the concentration of 2 mg/ml was prepared in RO DI water.
- a 0.2 ml of 25 mM DTT solution was added into this F108-PDS solution and the mixture was allowed to react for 10 minutes at room temperature. The DTT will break the disulfide bound of PDS and release the 2-thiopyridone molecules into the solution.
- the UN absorbance (A) of this solution at wavelength of 343 nm was measured.
- the partial thromboplastin time test is used to determine the amount of time it takes for blood to coagulate when exposed to various substances or surfaces.
- the PTT is used as a general screening test for the detection of coagulation abnormalities in the intrinsic pathway.
- the PTT was used to test the effectiveness of the PluronicTM F108. coating on the surface of a polysulfone membrane used in a dialyzer.
- the polysulfone membranes from six dialyzers were used in this test: (1) uncoated polysulfone; (2) PluronicTM F108 [(PEO) ⁇ 29 -(PPO) 5 6-(PEO) ⁇ 29 ] (purchased from BASF) coated polysulfone; (3) Acrylonitrile — Sodium Methally Sulfone; (4) Cellulose; (5) Polyethersulfone; and (6) PEO coated Cellulose.
- the study also included two additional samples that were tested under the same conditions: a negative control sample that included only plasma and no membrane material, and a positive control sample that contained glass beads instead of a membrane material.
- the dialyzer membranes used in this test were coated with the single coating process described above and sent to the Nelson Laboratories in Salt Lake City, Utah which performed the PTT test in accordance with the Nelson Laboratories protocol NO200013003-01.
- the membrane was placed in a test tube containing 200 ul human plasma and incubated at 22°C for 60 minutes.
- the human plasma contained 0.01 M of sodium citrate.
- the test tube containing the prepared PTT reagents and 0.02 M CaCl 2 was placed in a 37°C water bath to increase the test tube temperature to 37°C.
- 200 ul.PTT reagent was transferred.into one sample test tube and incubated at 37°C for exactly three minutes.
- 200 ul of 0.02 M CaCl 2 solution at a temperature of 37°C was added to the test tube and mixed well. The time it took for a blood clot to form in the test tube was measured and recorded.
- FIG. 14 shows the average clotting time for each of the 8 samples tested.
- the extensions on the top of the bar graph for each of the 7 samples (other than the negative control sample) show the magnitude of error in the average clot time.
- Table 2 shows the clotting time ratio for each of the seven samples as compared to the negative control sample.
- the clotting time ratio is equal to the plasma clotting time of the sample divided by the plasma clotting time of the negative control.
- the plasma clotting time for the negative control is 100%).
- the higher percentage of the clotting time ratio indicates that the plasma needed a longer time to clot and that the material is, therefore, more hemocompatible.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003550824A JP2005511208A (en) | 2001-12-07 | 2002-12-06 | Copolymer coating of hydrophobic membrane |
EP02797221A EP1450938A2 (en) | 2001-12-07 | 2002-12-06 | Copolymer coating for a hydrophobic membrane |
AU2002362089A AU2002362089A1 (en) | 2001-12-07 | 2002-12-06 | Copolymer coating for a hydrophobic membrane |
CA002465260A CA2465260A1 (en) | 2001-12-07 | 2002-12-06 | Copolymer coating for a hydrophobic membrane |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/013,323 US20030148017A1 (en) | 2001-12-07 | 2001-12-07 | Copolymer coating for a hydrophobic membrane |
US10/013,323 | 2001-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003049775A2 true WO2003049775A2 (en) | 2003-06-19 |
WO2003049775A3 WO2003049775A3 (en) | 2004-01-22 |
Family
ID=21759372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/039171 WO2003049775A2 (en) | 2001-12-07 | 2002-12-06 | Copolymer coating for a hydrophobic membrane |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030148017A1 (en) |
EP (1) | EP1450938A2 (en) |
JP (1) | JP2005511208A (en) |
AU (1) | AU2002362089A1 (en) |
CA (1) | CA2465260A1 (en) |
WO (1) | WO2003049775A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008073530A1 (en) * | 2006-12-15 | 2008-06-19 | General Electric Company | Polyarylether membranes |
US7669720B2 (en) | 2006-12-15 | 2010-03-02 | General Electric Company | Functional polyarylethers |
US7977451B2 (en) | 2006-12-15 | 2011-07-12 | General Electric Company | Polyarylether membranes |
US8118176B2 (en) | 2003-08-28 | 2012-02-21 | Gambro Ab | Membrane unit element, semipermeable membrane, filtration device, and processes for manufacturing the same |
US8602221B2 (en) * | 2005-08-09 | 2013-12-10 | Asahi Kasei Kabuhiki Kaisha | Separation membrane for use in treatment of liquid comprising aromatic ether polymer hydrophilized with hydrophilizing agent |
EP2990099A1 (en) * | 2014-08-18 | 2016-03-02 | Fenwal, Inc. | Anti-thrombogenic porous membranes and methods for manufacturing such membranes |
KR20180111532A (en) * | 2017-03-30 | 2018-10-11 | 그리폴즈 월드와이드 오퍼레이션스 리미티드 | Device for therapeutic plasma exchange |
US12048794B2 (en) | 2017-03-30 | 2024-07-30 | Grifols Worldwide Operations Limited | Device for therapeutic plasma exchange |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060015057A1 (en) * | 2004-07-15 | 2006-01-19 | Ho Chih-Hu | Coating for arterial-venous blood tubing set for hemodialysis system |
KR100608482B1 (en) | 2005-06-10 | 2006-08-02 | 한양대학교 산학협력단 | Proton exchange membrane comprising compatibilizer and fuel cell comprising the same |
MX2008007716A (en) | 2005-12-13 | 2008-09-26 | Exthera Ab | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood. |
DE102009004848B3 (en) | 2009-01-16 | 2010-04-15 | Sartorius Stedim Biotech Gmbh | Electron beam-induced modification of membranes by polymers |
JP5925693B2 (en) | 2009-12-01 | 2016-05-25 | エクステラ・メディカル・コーポレーション | Method for removing cytokines from blood using surface-immobilized polysaccharides |
EP2558177A1 (en) | 2010-04-15 | 2013-02-20 | Fresenius Medical Care Holdings, Inc. | Anticoagulant-free dialysis systems and methods |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
US20130146541A1 (en) | 2011-12-13 | 2013-06-13 | Nxstage Medical, Inc. | Fluid purification methods, devices, and systems |
WO2013188073A1 (en) | 2012-06-13 | 2013-12-19 | Exthera Medical, Llc | Use of heparin and carbohydrates to treat cancer |
AU2014302884B2 (en) | 2013-06-24 | 2018-03-29 | Exthera Medical Corporation | Blood filtration system containing mannose coated substrate |
CA2928866C (en) | 2013-11-08 | 2021-11-09 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
JP2017513636A (en) | 2014-04-24 | 2017-06-01 | エクスセラ メディカル コーポレイション | Method for removing bacteria from blood using high flow rate |
EP3197342B1 (en) | 2014-09-22 | 2020-08-05 | ExThera Medical Corporation | Wearable hemoperfusion device |
EP3422943A4 (en) | 2016-03-02 | 2019-10-16 | ExThera Medical Corporation | Method for treating drug intoxication |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
US20180093032A1 (en) * | 2016-08-15 | 2018-04-05 | Henry John Smith | Targeted apheresis using binding agents or ligands immobilized on membranes |
WO2018126333A1 (en) * | 2017-01-03 | 2018-07-12 | 于杰 | Integrated blood purifier |
DE102019102597A1 (en) | 2019-02-01 | 2020-08-06 | DC Diagnostics Concept UG (haftungsbeschränkt) | Container for storing a body fluid |
JP2022543874A (en) * | 2019-08-09 | 2022-10-14 | ハイドロオクシス ホールディングス リミテッド | Water-wettable filtration membrane and its manufacture |
EP4061512A1 (en) | 2019-11-21 | 2022-09-28 | EMD Millipore Corporation | Hydrophilic membranes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698388A (en) * | 1983-04-30 | 1987-10-06 | Nippon Oil & Fats Co. | Method for modifying the surface of polymer materials |
US6319664B1 (en) * | 1996-10-24 | 2001-11-20 | Corning Incorporated | Low protein-binding polymer product produced using low HLB number non-ionic surfactant |
US6413621B1 (en) * | 1996-08-26 | 2002-07-02 | Massachusetts Institute Of Technology | Polymeric membranes and other polymer articles having desired surface characteristics and method for their preparation |
US6509098B1 (en) * | 1995-11-17 | 2003-01-21 | Massachusetts Institute Of Technology | Poly(ethylene oxide) coated surfaces |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4906375A (en) * | 1984-07-14 | 1990-03-06 | Fresenius, Ag | Asymmetrical microporous hollow fiber for hemodialysis |
WO1986007541A1 (en) * | 1985-06-19 | 1986-12-31 | Yasushi Zyo | Composition which can impart antithrombotic ability and medical apparatus to be in contact with blood |
WO1989002282A1 (en) * | 1987-09-21 | 1989-03-23 | Terumo Kabushiki Kaisha | Medical instrument and production thereof |
DE68923444D1 (en) * | 1988-09-22 | 1995-08-17 | Univ Utah | SUPER SURFACE-ACTIVE POLYMER AGENT FOR GIVING RESISTANCE TO PROTEINS AND ELIMINATING PROTEINS. |
US5516703A (en) * | 1993-08-20 | 1996-05-14 | The University Of Utah | Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands |
US6284503B1 (en) * | 1993-08-20 | 2001-09-04 | University Of Utah Research Foundation | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
US5463010A (en) * | 1993-11-12 | 1995-10-31 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Hydrocyclosiloxane membrane prepared by plasma polymerization process |
DE19515689A1 (en) * | 1995-04-28 | 1996-10-31 | Bayer Ag | Polysulfone / polyether block copolycondensates |
US5700902A (en) * | 1995-07-27 | 1997-12-23 | Circe Biomedical, Inc. | Block copolymers |
US5911880A (en) * | 1995-12-15 | 1999-06-15 | Research Corporation Technologies, Inc. | Self-wetting membranes from engineering plastics |
US5883150A (en) * | 1996-08-09 | 1999-03-16 | Millipore Corporation | Compositions of a copolymer including a sulfone polymer |
US5885456A (en) * | 1996-08-09 | 1999-03-23 | Millipore Corporation | Polysulfone copolymer membranes and process |
US6071406A (en) * | 1996-11-12 | 2000-06-06 | Whatman, Inc. | Hydrophilic polymeric phase inversion membrane |
US5900270A (en) * | 1997-09-22 | 1999-05-04 | Cobe Laboratories, Inc. | Technique for testing and coating a microporous membrane |
US5955588A (en) * | 1997-12-22 | 1999-09-21 | Innerdyne, Inc. | Non-thrombogenic coating composition and methods for using same |
US6087452A (en) * | 1998-06-02 | 2000-07-11 | University Of Utah | Metal-chelating surfacant |
-
2001
- 2001-12-07 US US10/013,323 patent/US20030148017A1/en not_active Abandoned
-
2002
- 2002-12-06 AU AU2002362089A patent/AU2002362089A1/en not_active Abandoned
- 2002-12-06 WO PCT/US2002/039171 patent/WO2003049775A2/en not_active Application Discontinuation
- 2002-12-06 JP JP2003550824A patent/JP2005511208A/en not_active Withdrawn
- 2002-12-06 CA CA002465260A patent/CA2465260A1/en not_active Abandoned
- 2002-12-06 EP EP02797221A patent/EP1450938A2/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698388A (en) * | 1983-04-30 | 1987-10-06 | Nippon Oil & Fats Co. | Method for modifying the surface of polymer materials |
US6509098B1 (en) * | 1995-11-17 | 2003-01-21 | Massachusetts Institute Of Technology | Poly(ethylene oxide) coated surfaces |
US6413621B1 (en) * | 1996-08-26 | 2002-07-02 | Massachusetts Institute Of Technology | Polymeric membranes and other polymer articles having desired surface characteristics and method for their preparation |
US6319664B1 (en) * | 1996-10-24 | 2001-11-20 | Corning Incorporated | Low protein-binding polymer product produced using low HLB number non-ionic surfactant |
US6565789B2 (en) * | 1996-10-24 | 2003-05-20 | Corning Incorporated | Methods for producing low binding surfaces |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8118176B2 (en) | 2003-08-28 | 2012-02-21 | Gambro Ab | Membrane unit element, semipermeable membrane, filtration device, and processes for manufacturing the same |
US8602221B2 (en) * | 2005-08-09 | 2013-12-10 | Asahi Kasei Kabuhiki Kaisha | Separation membrane for use in treatment of liquid comprising aromatic ether polymer hydrophilized with hydrophilizing agent |
WO2008073530A1 (en) * | 2006-12-15 | 2008-06-19 | General Electric Company | Polyarylether membranes |
US7669720B2 (en) | 2006-12-15 | 2010-03-02 | General Electric Company | Functional polyarylethers |
US7695628B2 (en) | 2006-12-15 | 2010-04-13 | General Electric Company | Polyarylether membranes |
US7977451B2 (en) | 2006-12-15 | 2011-07-12 | General Electric Company | Polyarylether membranes |
EP2990099A1 (en) * | 2014-08-18 | 2016-03-02 | Fenwal, Inc. | Anti-thrombogenic porous membranes and methods for manufacturing such membranes |
KR20180111532A (en) * | 2017-03-30 | 2018-10-11 | 그리폴즈 월드와이드 오퍼레이션스 리미티드 | Device for therapeutic plasma exchange |
KR102566825B1 (en) * | 2017-03-30 | 2023-08-11 | 그리폴즈 월드와이드 오퍼레이션스 리미티드 | Device for therapeutic plasma exchange |
US12048794B2 (en) | 2017-03-30 | 2024-07-30 | Grifols Worldwide Operations Limited | Device for therapeutic plasma exchange |
Also Published As
Publication number | Publication date |
---|---|
JP2005511208A (en) | 2005-04-28 |
CA2465260A1 (en) | 2003-06-19 |
AU2002362089A8 (en) | 2003-06-23 |
WO2003049775A3 (en) | 2004-01-22 |
US20030148017A1 (en) | 2003-08-07 |
EP1450938A2 (en) | 2004-09-01 |
AU2002362089A1 (en) | 2003-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030148017A1 (en) | Copolymer coating for a hydrophobic membrane | |
KR101157244B1 (en) | Process for producing modified substrate and process for modifying separation membrane system | |
JP4059543B2 (en) | Medical device for extracorporeal treatment of blood or plasma and method for manufacturing the device | |
Wenten et al. | Advances in polysulfone-based membranes for hemodialysis | |
EP1388364A1 (en) | Asymmetric porous films and process for producing the same | |
JPWO2002009857A1 (en) | Modified hollow fiber membrane | |
Matsuda et al. | Solute removal efficiency and biocompatibility of the high-performance membrane–from engineering points of view | |
JP5633277B2 (en) | Separation membrane module | |
JP3126749B2 (en) | Composite material compatible with blood | |
JPWO2007010961A1 (en) | Modified substrate and production method thereof | |
EP0570232A2 (en) | Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol | |
Masaki et al. | Effect of permeability on indices of haemodialysis membrane biocompatibility. | |
EP3195930B1 (en) | Fiber for protein adsorption and column for protein adsorption | |
JP2003033432A (en) | Blood purifying film | |
JP2002102692A (en) | Manufacturing method for lipoperoxide-adsorbing material | |
JP4830181B2 (en) | Hollow fiber membrane for lipid peroxide adsorption and module using the same | |
JP4802537B2 (en) | Modified substrate | |
JP4797327B2 (en) | Method for treating substrate and method for producing separation membrane using the method | |
Mahliçli | Preparation and characterization of hemodialysis membranes | |
Mahlıçlı | Preparation and Characterization of Hemodialysis Membranes | |
JP2005231286A (en) | Modified substrate | |
HOENICH | Membranes and permeable films NA HOENICH, University of Newcastle upon Tyne, UK and D MALIK, Loughborough University, UK |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2465260 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002797221 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003550824 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002797221 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002797221 Country of ref document: EP |